Printer Friendly

Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-123 Treatment For Acne Vulgaris In Lotion Form.

ENPNewswire-August 8, 2019--Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-123 Treatment For Acne Vulgaris In Lotion Form

(C)2019 ENPublishing -

Release date- 07082019 - Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-123 (tazarotene 0.045%) Lotion with a PDUFA action date of Dec. 22, 2019.

If approved, IDP-123 will be the first tazarotene acne treatment available in a lotion form.

'Millions of Americans are affected by acne and, for many of these patients, it can be difficult to find a treatment that works for them,' said Bill Humphries, president, Ortho Dermatologics. 'If approved, IDP-123 will offer physicians and their patients a lower concentration of tazarotene in a lotion formulation, helping to further expand upon our growing portfolio of acne treatments.'

The NDA submitted for IDP-123 includes data from two successfully completed Phase 3 randomized, placebo-controlled, double-blind clinical trials in 1,614 patients with moderate to severe acne. The primary efficacy endpoints included the absolute change in the mean noninflammatory and inflammatory lesion counts, the percentage of subjects who had a least a two-grade improvement from baseline to week 12 in the Evaluator Global Severity Score (EGSS) and who had 'clear' or 'almost clear' skin. In both Phase 3 studies, all primary efficacy endpoints were met with statistical significance (p

((Distributed via M2 Communications -

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ENP Newswire
Date:Aug 8, 2019
Previous Article:Arvinas to Present at the Wedbush PacGrow Healthcare Conference.
Next Article:Ra Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters